Name
RF6-03: Efficacy and safety of DP303c versus T-DM1 in HER2-positive advanced breast cancer: Interim analysis of a randomized, open-label, phase 3 trial - Commentary By: Giuseppe Curigliano, MD, PhD
Date & Time
Tuesday, December 2, 2025
Speakers
Virtual Session Link
Total Minutes
04:59
OnDemand Video URL